Congress creates federal drug factory to bypass pharma pricing
H.R. 7854 — Medicines for the People Act · Filed by Rashida Tlaib (D-MI) · 4 cosponsors · Introduced Mar 5, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new National Institute for Biomedical Research and Development within the NIH to conduct full-cycle drug, device, and biological product development with the explicit goal of making medicines available to the public at equitable and accessible prices. The Institute would own patents and trade secrets from federally funded research, license them to the Medicines Patent Pool and other entities under cost-plus and non-exclusive terms, conduct public manufacturing where practicable, and share all clinical trial data and research findings transparently. A 15-member governing board with strict conflict-of-interest rules (excluding pharma lobbyists, executives from companies with federal settlements, and those with financial interests) would oversee priorities focused on unmet public health needs rather than market profitability.
Why we flagged it
The bill's core mechanism is establishing a federal institute to develop and manufacture medicines at cost, own resulting patents, and license them under terms that prioritize public access over private profit. This is fundamentally a public-sector drug development and pricing control measure, not a subsidy or deregulation.
What the text implies
- The bill grants the federal government ownership of all patents and trade secrets from federally funded research, including work conducted through private contractors—a significant shift in IP allocation that may deter some private R&D partnerships unless the public interest licensing terms prove attractive.
- Mandatory licensing to the Medicines Patent Pool and non-exclusive terms for for-profit entities may reduce incentives for private pharmaceutical companies to participate in Institute-funded research or to license resulting patents, potentially fragmenting the drug development ecosystem.
The full analysis lists 5 implications of this text.
Who stands to gain
patients and consumers (lower medicine prices); public health programs (reduced drug costs); nonprofit organizations (free patent licenses)